Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, October 4, 2016
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States
Friday, September 30, 2016
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma
Thursday, September 29, 2016
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016
Wednesday, September 28, 2016
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Treatment of non-infectious Uveitis
Eisai Commences Provision of "EMILY" Smartphone App to Support Living with Epilepsy in Japan
Eisai Submits Supplemental Application for Partial Label Change for Antiepileptic Drug Fycompa
Thursday, September 15, 2016
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma
Friday, August 26, 2016
Anticancer Agent "Treakisym for Injection 100 mg" Approved in Japan for Additional Indication of Chronic Lymphocytic Leukemia
Tuesday, August 23, 2016
Eisai to Launch Chocola BB Mouth Ulcer Repair Shot
Monday, August 1, 2016
Eisai Presents Results of Additional Analysis of Phase III Study of Anticancer Agent Halaven at 14th JSMO Annual Meeting Plenary Session

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: